Arcutis Biotherapeutics Inc DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review - Conference Call Transcript
Good day, ladies and gentlemen and welcome to the Arcutis Conference Call.
As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Ms. Heather Armstrong, Vice President of Investor Relations and Corporate Communications. You may begin.
Thank you. Good morning and welcome to our conference call and webcast to discuss our positive topline results from the DERMIS-1 and DERMIS-2 Pivotal Phase 3 studies evaluating roflumilast cream as a potential topical treatment for plaque psoriasis.
The slide views in today's webcast can be found under events and presentations and the investor section of our website at arcutis.com.
I'm joined on the call today by Frank Watanabe, President and CEO. Dr. Patrick Burnett, Chief Medical Officer; Dr. Mark Lebwohl, Professor and Dean for Clinical Therapeutics at the Icahn School of Medicane at Mount Sinai; Ken Lock, Chief Commercial Officer; and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |